Skip to main content
. 2018 May 30;16(2):529–536. doi: 10.3892/etm.2018.6235

Figure 2.

Figure 2.

Effect of antitumor necrosis factor-α antibodies on the viability of hepatocellular carcinoma cell lines via ADCC and CDC. No significant differences in the direct cytotoxic effects between infliximab and etanercept were observed on (A) HepG2 and (B) Hep3B cells. No significant difference in the ADCC effects between infliximab and etanercept were observed on (C) HepG2 and (D) Hep3B cells. A significant difference in the CDC effects was observed between infliximab and etanercept on (E) HepG2 and (F) Hep3B cells. *P<0.05. ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity.